JP2023508332A5 - - Google Patents
Info
- Publication number
- JP2023508332A5 JP2023508332A5 JP2022538232A JP2022538232A JP2023508332A5 JP 2023508332 A5 JP2023508332 A5 JP 2023508332A5 JP 2022538232 A JP2022538232 A JP 2022538232A JP 2022538232 A JP2022538232 A JP 2022538232A JP 2023508332 A5 JP2023508332 A5 JP 2023508332A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- cancer
- substituted
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952032P | 2019-12-20 | 2019-12-20 | |
| US62/952,032 | 2019-12-20 | ||
| PCT/US2020/065410 WO2021127045A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508332A JP2023508332A (ja) | 2023-03-02 |
| JP2023508332A5 true JP2023508332A5 (enExample) | 2023-12-25 |
| JP7750526B2 JP7750526B2 (ja) | 2025-10-07 |
Family
ID=76478077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538232A Active JP7750526B2 (ja) | 2019-12-20 | 2020-12-16 | 組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230054854A1 (enExample) |
| EP (1) | EP4069242A4 (enExample) |
| JP (1) | JP7750526B2 (enExample) |
| KR (1) | KR20220119420A (enExample) |
| CN (2) | CN121102230A (enExample) |
| AU (1) | AU2020404996A1 (enExample) |
| BR (1) | BR112022012283A2 (enExample) |
| CA (1) | CA3165474A1 (enExample) |
| IL (1) | IL294094A (enExample) |
| MX (1) | MX2022007623A (enExample) |
| TW (1) | TWI875898B (enExample) |
| WO (1) | WO2021127045A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023147297A2 (en) * | 2022-01-25 | 2023-08-03 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102124715B1 (ko) * | 2015-11-03 | 2020-06-18 | 제넨테크, 인크. | 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물 |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| KR20200108301A (ko) * | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| WO2019165204A1 (en) * | 2018-02-23 | 2019-08-29 | Newave Pharmaceutical Inc. | 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase |
| US12220415B2 (en) * | 2018-02-28 | 2025-02-11 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
-
2020
- 2020-12-16 AU AU2020404996A patent/AU2020404996A1/en active Pending
- 2020-12-16 KR KR1020227024701A patent/KR20220119420A/ko active Pending
- 2020-12-16 IL IL294094A patent/IL294094A/en unknown
- 2020-12-16 BR BR112022012283A patent/BR112022012283A2/pt unknown
- 2020-12-16 CN CN202511346658.2A patent/CN121102230A/zh active Pending
- 2020-12-16 US US17/757,530 patent/US20230054854A1/en active Pending
- 2020-12-16 WO PCT/US2020/065410 patent/WO2021127045A1/en not_active Ceased
- 2020-12-16 JP JP2022538232A patent/JP7750526B2/ja active Active
- 2020-12-16 MX MX2022007623A patent/MX2022007623A/es unknown
- 2020-12-16 CA CA3165474A patent/CA3165474A1/en active Pending
- 2020-12-16 EP EP20904098.9A patent/EP4069242A4/en active Pending
- 2020-12-16 CN CN202080095323.7A patent/CN115135325B/zh active Active
- 2020-12-18 TW TW109145167A patent/TWI875898B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508332A5 (enExample) | ||
| JP2023508328A5 (enExample) | ||
| JP2021516242A5 (enExample) | ||
| JP2022141916A5 (enExample) | ||
| RU2020120928A (ru) | Бензамидные соединения | |
| JP2023526283A5 (enExample) | ||
| ES2591028T3 (es) | Composiciones de inhibidores de quinasa y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con quinasas | |
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| JP2023507797A5 (enExample) | ||
| JP2019514854A5 (enExample) | ||
| RU2007134396A (ru) | Химические соединения | |
| RU2589713C2 (ru) | Средство, усиливающее действие противоопухолевых средств | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| TWI755788B (zh) | 類鐸受體促效劑 | |
| JP2023508327A5 (enExample) | ||
| CA3126102A1 (en) | Substituted polycyclic carboxylic acids, analogues thereof, and methods using same | |
| JP7410950B2 (ja) | 置換アリールメチル尿素およびヘテロアリールメチル尿素、その類似体、ならびにそれらを使用する方法 | |
| JP2006519862A5 (enExample) | ||
| CN105408321A (zh) | 新的吲哚和吡咯衍生物、它们的制备方法和含有它们的药物组合物 | |
| ES2919572T3 (es) | Compuestos antiproliferación y usos de los mismos | |
| WO2018117177A1 (ja) | Ｂｒｋ阻害化合物 | |
| WO1995003307A1 (en) | Brain cell protective | |
| JP2021512046A5 (enExample) | ||
| JP2024516828A (ja) | がん治療のためのｐｃｎａ阻害剤及びｅｇｆｒ阻害剤 | |
| CN107708700A (zh) | 用于治疗癌症的方法 |